mirabegron

Adult Dosing

Overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and urinary frequency

Starting dose: 25mg PO qd. The medication is effective within 8 weeks. The dose can be increased to 50mg PO qd according to individual tolerability and efficacy

Note:

Dose should be taken with water and swallowed whole. It should not be divided, chewed or crushed

Pediatric Dosing

[Outline]

Indications ⬆ ⬇

Overactive bladder (OAB) with symptoms urinary incontinence, urgency, and urinary frequency

Contraindications ⬆ ⬇

Black Box Warnings ⬆ ⬇

Dosing Adjustment ⬆ ⬇

Renal Dose Adjustment

Mild-moderate renal impairment: No dose adjustments
Severe renal impairment (CLcr 15 to 29 mL/min or eGFR 15 to 29 mL/min/1.73 m²): Max dose 25 mg
End stage renal disease: Use not recommended

Hepatic Dose Adjustment

Warnings/Precautions ⬆ ⬇

Mirabegron may lead to an increase in blood pressure. Periodic monitoring is advisable in hypertensive patients
Closely monitor and adjust dose while coadministering with drugs having narrow therapeutic index metabolized by CYP2D6, such as thioridazine, flecainide, and propafenone; caution advised

Cautions: Use cautiously in

Interactions ⬆ ⬇

Myrbetriq interacts with :

Pregnancy/Breast Feeding ⬆ ⬇

Pregnancy Category:C

Breastfeeding: It is unknown whether mirabegron is excreted in human milk, manufacturer advises caution

Adverse Reactions ⬆ ⬇

Clinical Pharmacology ⬆ ⬇

Beta-3 adrenergic receptor agonist; relaxes the detrusor smooth muscle during the storage phase of the urinary bladder and increases bladder capacity
Absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg
Metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis
Excretion in urine 55% and in feces 34%. Unchanged form of the drug recovered was 25% in urine and 0% in feces
Half-life: 50 hours

Brands and Availability ⬆ ⬇